Core Viewpoint - Ganli Pharmaceutical announced that it will not repurchase shares by July 2025 [2] Summary by Relevant Sections - Company Announcement - Ganli Pharmaceutical released a statement on August 1, indicating that it will not engage in share repurchases until July 2025 [2]

Core Viewpoint - Ganne Li Pharmaceutical announced that it will hold a semi-annual performance briefing on August 13, 2025, from 10:00 to 11:00 AM [2] Company Summary - The company is scheduled to present its half-year performance results for 2025 [2]

金融界消息 截至2025年8月1日收盘，甘李药业（603087）报收于60.99元，上涨5.34%，换手率5.14%， 成交量28.84万手，成交金额17.55亿元。 资金流向方面，今日主力资金净流入3409.28万元，占比成交额1.94%。其中，超大单净流入6145.27万 元、占成交额3.5%，大单净流出2736.00万元、占成交额1.56%，中单净流出流出3790.35万元、占成交 额2.16%，小单净流入381.07万元、占成交额0.22%。 天眼查商业履历信息显示，甘李药业股份有限公司，成立于1998年，位于北京市，是一家以从事医药制 造业为主的企业。企业注册资本60106.529万人民币，实缴资本60106.529万人民币。公司法定代表人为 陈伟。 通过天眼查大数据分析，甘李药业股份有限公司共对外投资了6家企业，参与招投标项目2427次，知识 产权方面有商标信息190条，专利信息103条，此外企业还拥有行政许可449个。 来源：金融界 甘李药业最新一期业绩显示，截至2025一季报，公司营业总收入9.85亿元、同比增长75.76%，归属净利 润3.12亿元，同比增长224.90%，扣非净利润2.15 ...

证券代码：603087 证券简称：甘李药业 公告编号：2025-056 甘李药业股份有限公司 关于召开 2025 年半年度业绩说明会的公告 重要内容提示： 公司将于 2025 年 8 月 8 日在上海证券交易所网站（www.sse.com.cn）披露 《2025 年半年度报告》。为便于广大投资者更全面深入地了解公司状况，公司决 定于 2025 年 8 月 13 日上午 10:00-11:00 举行 2025 年半年度业绩说明会，对公司 的经营业绩、公司战略等具体情况进行充分交流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2025 年半年度公司的 经营业绩、公司战略等具体情况与投资者进行互动交流和沟通，在信息披露允许 的范围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 会议召开时间：2025 年 8 月 13 日（星期三）上午 10:00-11:00 会议召开地点：上海证券交易所上证路演中心（网址：https://roadshow.sseinf o.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 8 月 6 日（星期三）至 8 月 12 日 ...

格隆汇8月1日丨甘李药业(603087.SH)公布，截至2025年7月31日，公司已累计回购股份354.0021万股， 占公司总股本的比例为0.5890%，成交最高价为45.14元/股，成交最低价为37.65元/股，已支付的资金总 额约为人民币15,006.9654万元（不含交易费用）。 ...

证券代码：603087 证券简称：甘李药业 公告编号：2025-057 甘李药业股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 回购方案首次披露日 | 2024/9/6 | | | | | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 月 月 2024 9 9 4 | 5 日~2025 | 年 | 日 | | 预计回购金额 | 15,000万元~30,000万元 | | | | | 回购用途 | √减少注册资本 | | | | | | □用于员工持股计划或股权激励 | | | | | | □用于转换公司可转债 | | | | | | □为维护公司价值及股东权益 | | | | | 累计已回购股数 | 354.0021万股 | | | | | 累计已回购股数占总股本比例 | 0.5890% | | | | | 累计已回购金额 | 15,006.9654万元 | | | | | 实际回购价格区间 | 37.65元/股~45. ...

Investment Rating - The report maintains a positive outlook on the pharmaceutical and biotechnology industry, emphasizing the transition from "Made in China" to "Created in China" for innovative drugs [10]. Core Insights - The report highlights that domestic innovative drugs are gaining global competitiveness and are currently in the first and second stages of international expansion, primarily through licensing agreements and partnerships [10][12]. - The report identifies key areas of focus for investment, including PD-(L)1 plus, ADCs, and GLP-1 drugs, which are expected to drive future growth and business development (BD) opportunities [10][51]. Summary by Sections Section 1: Transition from "Manufacturing" to "Innovation" - The policy reforms initiated in 2015 have stimulated a shift from generic to innovative drug development in China, with significant increases in R&D investment since 2018 [19][21]. - The number of First-in-Class (FIC) drugs developed in China has risen from 9 in 2015 to 120 in 2024, indicating a substantial increase in innovation [25][26]. Section 2: Continued BD Opportunities - PD-(L)1 plus is identified as a cornerstone for next-generation cancer treatments, with significant demand and potential for new products [51]. - The report notes that ADCs are transitioning towards more differentiated targets, focusing on unmet clinical needs, with promising candidates like PD-L1, DLL3, and EGFR [51]. - The GLP-1 market is experiencing rapid growth, with a focus on multi-target, oral, combination, and long-acting formulations [51]. Section 3: Investment Recommendations - For PD-(L)1 plus, companies such as Kangfang Biotech, Shansheng Pharmaceutical, and Junshi Biosciences are recommended for investment due to their strong pipelines [5]. - In the ADC space, companies like Fuhong Hanlin and Zai Lab are highlighted for their potential in addressing unmet clinical needs [5]. - In the GLP-1 sector, firms such as Borui Pharmaceutical and Zai Lab are noted for their promising developments [5].

Group 1 - The core viewpoint is that the innovative pharmaceutical ETF (560900) has shown significant growth in both scale and trading activity, indicating strong market interest in the sector [1][2] - As of July 31, the innovative pharmaceutical ETF (560900) experienced a scale increase of 28.2 million yuan over the past two weeks, with a notable weekly share increase of 15 million shares, ranking first among comparable funds [1] - The underlying index, the CSI Innovative Pharmaceutical Industry Index (931152), rose by 0.26%, with key constituent stocks such as Ganli Pharmaceutical (603087) and Yifan Pharmaceutical (002019) showing substantial price increases of 6.48% and 3.67% respectively [1][2] Group 2 - In terms of capital inflow, the innovative pharmaceutical ETF (560900) recorded net inflows for 4 out of the last 5 trading days, totaling 16.87 million yuan [2] - Ganli Pharmaceutical's stock price surged over 7% on August 1, following positive developments in its international expansion, including approvals for its winter insulin formulation in Argentina and Malaysia [2] - Ganli Pharmaceutical's half-year profit forecast indicates a net profit of 600 million to 640 million yuan, representing a year-on-year growth of 100.73% to 114.12%, driven by significant revenue increases and effective cost management [2] Group 3 - The innovative pharmaceutical ETF (560900) closely tracks the CSI Innovative Pharmaceutical Industry Index, which selects up to 50 representative listed companies involved in innovative drug research and development [3] - The rise of AI-driven technology is creating new investment opportunities, prompting firms like Morgan Asset Management to integrate their global technology investment products to help investors capitalize on these trends [3]

Core Viewpoint - Dongfang Securities report highlights that Ganli Pharmaceutical's innovative drug data is impressive, particularly the glucose-lowering effects of GZR18, indicating strong future growth potential for the company [1] Group 1: Drug Development and Clinical Data - Ganli Pharmaceutical has leading R&D expenditures in the industry, with multiple key products gradually disclosing Phase II clinical data since 2025 [1] - GZR18 (Bofang Glutide) shows superior glucose-lowering effects in Type 2 diabetes patients, with HbA1c and weight reductions exceeding those of the Semaglutide group after 24 weeks of biweekly injections [1] - After 23 weeks of treatment, GZR18 subjects experienced an average weight loss of 6.92 kg, representing a 9.3% reduction from baseline [1] - The Phase II clinical data for GZR4, an insulin weekly formulation, indicates good safety and a more significant reduction in HbA1c compared to daily insulin degludec (Novo Nordisk) in patients with poor baseline insulin control after 16 weeks of treatment [1] Group 2: Market Outlook and Valuation - The company anticipates a substantial 32.6% increase in the volume of its third-generation insulin agreements in the upcoming centralized procurement in 2024, alongside a rebound in product prices [1] - Leveraging the market coverage advantages gained from centralized procurement, the company's annual performance expectations are further solidified [1] - The company is assigned a 37x PE valuation for 2025, corresponding to a target price of 70.67 yuan, maintaining a "buy" rating [1]

Investment Rating - The report maintains a "Buy" rating for the company [3][6]. Core Views - The company is expected to achieve significant growth in earnings per share, with projections of 1.91, 2.40, and 2.84 yuan for 2025-2027 respectively [3]. - The target price is set at 70.67 yuan based on a 37x PE valuation for 2025, reflecting a strong growth outlook [3]. - The company has demonstrated impressive revenue growth, with a forecasted increase in revenue from 2,608 million yuan in 2023 to 6,115 million yuan in 2027, representing a compound annual growth rate (CAGR) of 38.0% from 2025 to 2026 [5][12]. Financial Performance Summary - Revenue is projected to grow from 2,608 million yuan in 2023 to 6,115 million yuan in 2027, with year-on-year growth rates of 52.3%, 16.8%, 38.0%, 23.3%, and 18.0% respectively [5][12]. - Operating profit is expected to increase significantly, from 315 million yuan in 2023 to 2,014 million yuan in 2027, with growth rates of 155.4%, 100.3%, 115.5%, 25.4%, and 18.0% [5][12]. - Net profit attributable to the parent company is forecasted to rise from 340 million yuan in 2023 to 1,704 million yuan in 2027, with growth rates of 177.4%, 80.7%, 87.0%, 25.5%, and 18.1% [5][12]. - The company’s gross margin is projected to improve from 73.3% in 2023 to 75.8% in 2027, while net margin is expected to increase from 13.0% to 27.9% over the same period [5][12]. Clinical and Product Development Insights - The company has several promising products in its pipeline, including GZR18, which has shown superior glucose-lowering effects compared to competitors in clinical trials [10]. - GZR4, an insulin formulation, has also demonstrated significant efficacy in clinical trials, indicating strong potential for future revenue growth [10].